Stroke prevention in atrial fibrillation and 'real world' adherence to guidelines in the Balkan Region: The BALKAN-AF Survey

被引:45
|
作者
Potpara, Tatjana S. [1 ,2 ]
Dan, Gheorghe-Andrei [3 ]
Trendafilova, Elina [4 ]
Goda, Artan [5 ]
Kusljugic, Zumreta [6 ]
Manola, Sime [7 ]
Music, Ljilja [8 ]
Musetescu, Rodica [9 ]
Badila, Elisabeta [10 ]
Mitic, Gorana [11 ]
Paparisto, Vilma [5 ]
Dimitrova, Elena S. [4 ]
Polovina, Marija M. [1 ,2 ]
Petranov, Stanislav L. [12 ]
Djergo, Hortensia [5 ]
Loncar, Daniela [6 ]
Bijedic, Amira [6 ]
Brusich, Sandro [13 ]
Lip, Gregory Y. H. [1 ,2 ,14 ]
机构
[1] Univ Belgrade, Sch Med, Belgrade, Serbia
[2] Clin Ctr Serbia, Cardiol Clin, Belgrade, Serbia
[3] Med Univ Carol Davila, Colentina Univ Hosp, Bucharest, Romania
[4] Natl Heart Hosp, Sofia, Bulgaria
[5] Univ Hosp Ctr Mother Theresa, Clin Cardiol, Tirana, Albania
[6] Clin Internal Dis, Dept Cardiol, Tuzla, Bosnia & Herceg
[7] Clin Hosp Ctr Sestre Milosrdnice, Zagreb, Croatia
[8] Univ Clin Ctr Podgorica, Podgorica, Montenegro
[9] Cty Emergency Hosp, Ctr Cardiol, Craiova, Romania
[10] Med Univ Carol Davila, Dept Internal Med, Emergency Clin Hosp, Bucharest, Romania
[11] Clin Ctr Vojvodina, Novi Sad, Serbia
[12] Multiprofile Hosp Act Treatment, Burgas, Bulgaria
[13] Clin Hosp Ctr Rijeka, Rijeka, Croatia
[14] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England
来源
SCIENTIFIC REPORTS | 2016年 / 6卷
关键词
EUROPEAN COUNTRIES; FOLLOW-UP; MANAGEMENT; ANTICOAGULATION; RISK; ASPIRIN; PROGNOSIS; MORTALITY; WARFARIN; REGISTRY;
D O I
10.1038/srep20432
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Data on the management of atrial fibrillation (AF) in the Balkan Region are limited. The Serbian AF Association (SAFA) prospectively investigated contemporary 'real-world' AF management in clinical practice in Albania, Bosnia&Herzegovina, Bulgaria, Croatia, Montenegro, Romania and Serbia through a 14-week (December 2014-February 2015) prospective, multicentre survey of consecutive AF patients. We report the results pertinent to stroke prevention strategies. Of 2712 enrolled patients, 2663 (98.2%) with complete data were included in this analysis (mean age 69.1 +/- 10.9 years, female 44.6%). Overall, 1960 patients (73.6%) received oral anticoagulants (OAC) and 762 (28.6%) received antiplatelet drugs. Of patients given OAC, 17.2% received non-vitamin K antagonist oral anticoagulants (NOACs). CHA(2)DS(2)-VASc score was not significantly associated with OAC use. Of the 'truly low-risk' patients (CHA(2)DS(2)-VASc = 0 [males], or 1 [females]) 56.5% received OAC. Time in Therapeutic Range (TTR) was available in only 18.7% of patients (mean TTR: 49.5% +/- 22.3%). Age = 80 years, prior myocardial infarction and paroxysmal AF were independent predictors of OAC non-use. Our survey shows a relatively high overall use of OAC in AF patients, but with low quality of vitamin K antagonist therapy and insufficient adherence to AF guidelines. Additional efforts are needed to improve AF-related thromboprophylaxis in clinical practice in the Balkan Region.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation
    Beyer-Westendorf, Jan
    Ehlken, Birgit
    Evers, Thomas
    [J]. EUROPACE, 2016, 18 (08): : 1150 - 1157
  • [42] Stroke prevention in atrial fibrillation: the gap between guidelines and clinical practice
    Dan, G-A.
    Dan, A.
    Buzea, A.
    Tanasescu, R.
    Daha, I.
    Stanescu, C.
    [J]. EUROPEAN HEART JOURNAL, 2008, 29 : 208 - 208
  • [43] Are Primary Care Providers Meeting Guidelines for Stroke Prevention in Atrial Fibrillation?
    Cox, Jafna L.
    Parkash, Ratika
    Hamilton, Laura
    Thabane, Lehana
    Foster, Gary
    MacKillop, James
    Xie, Feng
    Ciaccia, Antonio
    Choudhri, Shurjeel
    Nemis-White, Joanna
    [J]. CIRCULATION, 2019, 140
  • [44] Aspirin, not without bleeding risk in the real world: results of a UK cohort study evaluating the use of antiplatelet therapy for stroke prevention in atrial fibrillation (AF)
    Ridha, E.
    Lacoin, L.
    Lefevre, C.
    Donaldson, R.
    Ramagopalan, S.
    Halcox, J.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 : 510 - 511
  • [45] Atrial fibrillation: estimated increased rate of stroke due to lacking adherence to guidelines
    Zehnder, Barbara S.
    Schaer, Beat A.
    Jeker, Urs
    Cron, Thomas A.
    Osswald, Stefan
    [J]. SWISS MEDICAL WEEKLY, 2006, 136 (47-48) : 757 - 760
  • [46] Preferences for and use of oral anticoagulants for stroke prevention in atrial fibrillation under real-world conditions in Germany: A survey among physicians
    Mocek, Anja
    Weber, Valeria
    Schmoelders, Johanna
    Witt, Henning
    Gothe, Holger
    [J]. PREVENTIVE MEDICINE REPORTS, 2022, 28
  • [47] Cost-effectiveness of warfarin: Trial versus "real-world" stroke prevention in atrial fibrillation
    Sorensen, Sonja V.
    Dewilde, Sarah
    Singer, Daniel E.
    Goldhaber, Samuel Z.
    Monz, Brigitta U.
    Plumb, Jonathan M.
    [J]. AMERICAN HEART JOURNAL, 2009, 157 (06) : 1064 - 1073
  • [48] How to REVISIT the increasing "real world" evidence for stroke prevention in non-valvular atrial fibrillation?
    Lip, Gregory Y. H.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (12) : 2055 - 2057
  • [49] Bleeding and Stroke Risk in a Real-world Prospective Primary Prevention Cohort of Patients With Atrial Fibrillation
    Poli, Daniela
    Testa, Sophie
    Antonucci, Emilia
    Grifoni, Elisa
    Paoletti, Oriana
    Lip, Gregory Y. H.
    [J]. CHEST, 2011, 140 (04) : 918 - 924
  • [50] Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter
    Cairns, John A.
    Connolly, Stuart
    McMurtry, Sean
    Stephenson, Michael
    Talajic, Mario
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2011, 27 (01) : 74 - 90